An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

November 8, 2020

Study Completion Date

November 8, 2020

Conditions
Healthy Subjects
Interventions
DRUG

Tavapadon tablet

Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily \[QD\] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)

DRUG

Tavapadon [14C] suspension

Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of \[14C\] Tavapadon on Day 16

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc., Madison

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT04241393 - An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects | Biotech Hunter | Biotech Hunter